N-(4-ethylphenyl)-N-isobutyl-3-(S-methylsulfonimidoyl)-4-((tetrahydro-2H-pyran-4-yl)methoxy)benzenesulfonamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(4-ethylphenyl)-N-isobutyl-3-(S-methylsulfonimidoyl)-4-((tetrahydro-2H-pyran-4-yl)methoxy)benzenesulfonamide
• 英文别名: N-(4-ethylphenyl)-N-(2-methylpropyl)-3-(methylsulfonimidoyl)-4-(oxan-4-ylmethoxy)benzenesulfonamide
• 化学式: C₂₅H₃₆N₂O₅S₂
• 分子量: 508.703
• InChiKey: OZSLLZRELNMFLA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  34
• 可旋转键数：
  10
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  114
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  N-(4-ethylphenyl)-N-isobutyl-3-(S-methylsulfonimidoyl)-4-((tetrahydro-2H-pyran-4-yl)methoxy)benzenesulfonamide 在 Chiralpak IA 作用下， 以 甲醇 、 二氯甲烷 、 乙腈 为溶剂， 反应 24.0h， 生成 (5-(N-(4-ethylphenyl)-N-isobutylsulfamoyl)-2-((tetrahydro-2H-pyran-4-yl)methoxy)phenyl)(methyl)(oxo)-l6-sulfaniminium ((1R,4S)-7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-yl)methanesulfonate
  参考文献：
  名称：

  Route scouting and optimization of a potent sulfoximine-based inverse agonist of RORγt

  摘要：

  During our research looking for novel inverse agonists of ROR gamma t, we identified a potent sulfoximine-based modulator as one of our pre-clinical candidates for the topical treatment for psoriasis. Herein, we describe the various routes we evaluated during the lead generation and optimization phases and the final route chosen for scale-up to deliver the first 100 g of API. (C) 2018 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2018.08.043
• 作为产物：
  描述：

  2-羟基茴香硫醚 在 氯磺酸 、 N-溴代丁二酰亚胺(NBS) 、 ruthenium(III) trichloride hydrate 、 potassium tert-butylate 、 potassium carbonate 、 高碘酸 、 N,N-二异丙基乙胺 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 水 、 甲苯 、 乙腈 为溶剂， 反应 24.17h， 生成 N-(4-ethylphenyl)-N-isobutyl-3-(S-methylsulfonimidoyl)-4-((tetrahydro-2H-pyran-4-yl)methoxy)benzenesulfonamide
  参考文献：
  名称：

  Route scouting and optimization of a potent sulfoximine-based inverse agonist of RORγt

  摘要：

  During our research looking for novel inverse agonists of ROR gamma t, we identified a potent sulfoximine-based modulator as one of our pre-clinical candidates for the topical treatment for psoriasis. Herein, we describe the various routes we evaluated during the lead generation and optimization phases and the final route chosen for scale-up to deliver the first 100 g of API. (C) 2018 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2018.08.043

文献信息

• BENZENESULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T))
  申请人：GALDERMA RESEARCH & DEVELOPMENT

  公开号：US20180170869A1

  公开（公告）日：2018-06-21

  Benzenesulfonamide derivatives of formula (I), the pharmaceutically acceptable addition salts thereof, the hydrates and/or solvates thereof, and the use of same as inverse agonist of retinoid-related orphan receptor gamma (RORγt) are described. A pharmaceutical composition including such compounds, as well as the use thereof for the topical and/or oral treatment of RORγt receptor-medicated inflammatory diseases, in particular acne, psoriasis and/or atopic dermatitis are also described.

  本文描述了式(I)的苯磺酰胺衍生物，以及其药学上可接受的加合物盐、水合物和/或溶剂合物，并将其用作视黄醇相关孤儿受体γ（RORγt）的逆拮抗剂。还描述了包含这些化合物的药物组合物，以及将其用于局部和/或口服治疗RORγt受体介导的炎症性疾病，特别是痤疮、银屑病和/或特应性皮炎。
• Benzenesulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (RORγ(T))
  申请人：GALDERMA RESEARCH & DEVELOPMENT

  公开号：US10457637B2

  公开（公告）日：2019-10-29

  Benzenesulfonamide derivatives of formula (I), the pharmaceutically acceptable addition salts thereof, the hydrates and/or solvates thereof, and the use of same as inverse agonist of retinoid-related orphan receptor gamma (RORγt) are described. A pharmaceutical composition including such compounds, as well as the use thereof for the topical and/or oral treatment of RORγt receptor-medicated inflammatory diseases, in particular acne, psoriasis and/or atopic dermatitis are also described.

  本发明描述了式(I)的苯磺酰胺衍生物、其药学上可接受的加成盐、其水合物和/或溶解物，以及其作为维甲酸相关孤儿受体γ（RORγt）的逆激动剂的用途。此外，还描述了一种包括此类化合物的药物组合物，以及将其用于局部和/或口服治疗 RORγt 受体引起的炎症性疾病，特别是痤疮、牛皮癣和/或特应性皮炎的方法。
• Sulfoximines as potent RORγ inverse agonists
  作者：Gilles Ouvry、Franck Bihl、Claire Bouix-Peter、Olivier Christin、Claire Defoin-Platel、Sophie Deret、Christophe Feret、David Froude、Feriel Hacini-Rachinel、Craig S. Harris、Catherine Hervouet、Guillaume Lafitte、Anne-Pascale Luzy、Branislav Musicki、Danielle Orfila、Veronique Parnet、Coralie Pascau、Jonathan Pascau、Romain Pierre、Catherine Raffin、Patricia Rossio、Delphine Spiesse、Nathalie Taquet、Etienne Thoreau、Rodolphe Vatinel、Emmanuel Vial、Laurent F. Hennequin

  DOI：10.1016/j.bmcl.2018.03.041

  日期：2018.5

  Progress in the identification of suitable RORc inverse agonists as clinical candidates has been hampered by the high lipophilicity that seems required for high potency on this nuclear receptor. In this context, we decided to focus on the replacement of the hydroxymethyl group found on known modulators to determine if more polarity could be tolerated in this position. SAR of the replacement of this moiety is presented in this article leading to the identification of sulfoximine derivatives as potent modulators with pharmacological activity in the in vivo mouse Imiquimod psoriasis model. (C) 2018 Elsevier Ltd. All rights reserved.
• DÉRIVÉS BENZÈNESULFONAMIDES EN TANT QU'AGONISTES INVERSES DU RÉCEPTEUR GAMMA ORPHELIN ASSOCIÉ AUX RÉTINOÏDES ROR GAMMA (T)
  申请人：Galderma Research & Development

  公开号：EP3233848B1

  公开（公告）日：2019-01-30
• [EN] BENZENESULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T))<br/>[FR] DÉRIVÉS BENZÈNESULFONAMIDES EN TANT QU'AGONISTES INVERSES DU RÉCEPTEUR GAMMA ORPHELIN ASSOCIÉ AUX RÉTINOÏDES ROR GAMMA (T)
  申请人：GALDERMA RES & DEV

  公开号：WO2016097389A1

  公开（公告）日：2016-06-23

  La présente invention concerne des dérivés benzènesulfonamides de formule (I), leurs sels d'addition pharmaceutiquement acceptables, leurs hydrates et/ou leurs solvates, ainsi que leur utilisation en tant qu'agonistes inverses du récepteur gamma orphelin associé aux rétinoïdes RORyt. L'invention est également relative aux compositions pharmaceutiques comprenant de tels composés, ainsi que leur utilisation pour le traitement par voie topique et/ou orale des maladies inflammatoires médiées par les récepteurs RORyt, notamment l'acné, le psoriasis et/ ou la dermatite atopique.